COVID-19: impact on blood and transfusion services
DOI:
https://doi.org/10.25758/set.2265Keywords:
COVID-19, Transfusion medicine, Convalescent plasma, Blood bankAbstract
A novel coronavirus emerged with an exponential and universal cycle of infection, carrying great morbidity and mortality rate. Since the patients suffer from the severe acute respiratory syndrome, the new virus designated as SARS-CoV-2, caused an outbreak and the pronouncement of a pandemic state, forcing people into isolation. The disease named Coronavirus disease 2019 (COVID-19) led to a drastic decline in blood supply and a new order of clinical transfusion proceedings management. The Portuguese Blood and Transplantation Institute with the other national responsible organizations formulated a normative contingency plan, in order to ensure and maintain a safe blood component support to all hospital requests. Regardless of the safety policies applied systematically in the transfusion process, such as routine nucleic acid tests in all donations, leukoreduction and pathogenic inactivation of blood components, the incomplete knowledge about the epidemiology and pathogenicity of SARS-CoV-2 suggests the precautionary principle. This lesson learned from previous outbreaks is a mandatory instruction in the transfusion medicine sector. Assuming the absence of vaccines and specific medication, reference laboratories of Blood and Transplantation Centers, Blood Functional Area, are intensively tagging the identification and screening of potential donors COVID-19 convalescent plasma as an alternative therapy.
Downloads
References
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953-66.
Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18(8):e217-27.
Guarner J. Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19. Am J Clin Pathol. 2020;153(4):420-1.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13-24.
Instituto Português do Sangue e da Transplantação. Plano de contingência para a sustentabilidade e segurança do fornecimento de sangue e componentes sanguíneos durante o surto de COVID-19: 3ª atualização, 27.03.2020. Lisboa: IPST; 2020.
World Health Organization. Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19): interim guidance 20 [homepage]. Geneva: WHO; 2020 [updated 2020 Jul 10]. Available from: https://www.who.int/publications/i/item/maintaining-a-safe-and-adequate-blood-supply-during-the-pandemic-outbreak-of-coronavirus-disease-(covid-19)
World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 [homepage]. Geneva: WHO; 2003. Available from: https://www.who.int/csr/sars/country/table2004_04_21/en/
World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [homepage]. Geneva: WHO; 2019. Available from: https://www.who.int/emergencies/mers-cov/en/
Shang G, Biggerstaff BJ, Yang B, Shao C, Farrugia A. Theoretically estimated risk of severe acute respiratory syndrome transmission through blood transfusion during an epidemic in Shenzhen, Guangdong, China in 2003. Transf Apher Sci. 2007;37(3):233-40.
Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020;34(2):75-80.
Schmidt M, Brixner V, Ruster B, Hourfar MK, Drosten C, Preiser W, et al. NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. Transfusion. 2004;44(4):470-5.
Seghatchian J, Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci. 2006;35(3):189-96.
Allain JP, Goodrich R. Pathogen reduction of whole blood: utility and feasibility. Transfus Med. 2017; 27 Suppl 5:320-6.
Mundt JM, Rouse L, Van den Bossche J, Goodrich RP. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol. 2014;90(5):957-64.
Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion. 2016;56(12):2948-52.
World Health Organization. Protecting the blood supply during infectious disease outbreaks: guidance for national blood services [homepage]. Geneva: WHO; 2019 Jan 2. Available from: https://www.who.int/publications/i/item/protecting-the-blood-supply-during-infectious-disease-outbreaks-guidance-for-national-blood-services
American Association of Blood Banks. AABB’s coronavirus resources [homepage]. Bethesda: AABB; 2020. Available from: http://www.aabb.org/advocacy/regulatorygovernment/Pages/AABB-Coronavirus-Resources.aspx
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90.
Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59(3):102790.
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study. medRxiv preprints. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.03.16.20036145v1
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-9.
Directorate General for Health and Food Safety. Medical products: quality, safety, innovation. Brussels: European Commission; 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Saúde e Tecnologia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal Saúde & Tecnologia offers immediate free access to its content, following the principle that making scientific knowledge available to the public free of charge provides greater worldwide democratization of knowledge.
The journal Saúde & Tecnologia does not charge authors any submission or article processing charges (APC).
All content is licensed under a Creative Commons CC-BY-NC-ND license. Authors have the right to: reproduce their work in physical or digital form for personal, professional, or teaching use, but not for commercial use (including the sale of the right to access the article); deposit on their website, that of their institution or in a repository an exact copy in electronic format of the article published by Saúde & Tecnologia, provided that reference is made to its publication in Saúde & Tecnologia and its content (including symbols identifying the journal) is not altered; publish in a book of which they are authors or editors the total or partial content of the manuscript, provided that reference is made to its publication in Saúde & Tecnologia.
